Slaughter and May, Cleary Gottlieb Steen & Hamilton and Bowman Gilfillan advised GlaxoSmithKline (GSK) on the sale of its remaining 6.2% stake in Aspen Pharmacare, announced last week.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact [email protected]
